Evaluation of the Safety and Efficacy of Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors

Trial Profile

Evaluation of the Safety and Efficacy of Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms FavorAx
  • Most Recent Events

    • 17 Oct 2017 Planned End Date changed from 1 Jan 2018 to 1 Aug 2018.
    • 17 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 11 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top